autologous anti-cd19 car-t cells caba-201
autologous anti-cd19 car-t cells caba-201: developed by 1 company · 5 clinical trials tracked.
autologous anti-cd19 car-t cells caba-201 evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could autologous anti-cd19 car-t cells caba-201 → CABA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cabaletta Bio, Inc. (CABA) Systemic Sclerosis; Relapsing Multiple Sclerosis (RMS); Pemp… | Phase 1/Phase 2 |
Clinical Trials (5)
RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis
Primary endpoint: Primary (Part A: Dose Escalation) incidence and severity of adverse events
RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis
Primary endpoint: To evaluate incidence and severity of adverse events (AEs)
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis
Primary endpoint: Phase 1/2: To evaluate incidence of adverse events
A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus
Primary endpoint: To evaluate incidence of adverse events
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris
Primary endpoint: Adverse events, including Dose Limit Toxicity
Frequently asked questions
Who is developing autologous anti-cd19 car-t cells caba-201?
autologous anti-cd19 car-t cells caba-201 is being developed by Cabaletta Bio, Inc..
How many clinical trials involve autologous anti-cd19 car-t cells caba-201?
BioSniper tracks 5 clinical trials involving autologous anti-cd19 car-t cells caba-201.